IBSA USA
Roberto Marrero is a seasoned financial executive with extensive experience in various leadership roles across prominent companies in the pharmaceutical and healthcare sectors. Currently serving as the Chief Financial Officer at IBSA USA and Yaral Pharma, Roberto previously held the position of Senior Finance Manager at Amgen, where responsibilities included managing a $400 million budget for clinical and commercial activities. With a strong background at Johnson & Johnson, Roberto demonstrated expertise in commercial finance and reporting for EMEA countries during an international assignment in Switzerland. Additional roles at CR Bard and Eli Lilly and Company further solidified skills in cost analysis, budgeting, and financial planning. Roberto holds a Bachelor's degree in Accounting and Finance from UPR Rio Piedras.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.